Figures computed from official regulatory filings — .
Analysttarget 21.08 USD (+69%) · consensus 4.73/5 · 14 buy · 1 hold · 0 sell
Ownershipinsiders 1.59% · institutions 123.11% · short 17.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Oric Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
11 buys124 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Heyman Richard A. | Exercise | $5.6K | SEC |
| Heyman Richard A. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Heyman Richard A. | Sell | $41.3K | SEC |
| Heyman Richard A. | Sell | $45.2K | SEC |
| Piscitelli Dominic | Exercise | $58.4K | SEC |
| Piscitelli Dominic | Sell | $181.3K | SEC |
| Piscitelli Dominic | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Piscitelli Dominic | Sell | $6.8K | SEC |
| Piscitelli Dominic | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Piscitelli Dominic | Exercise | $2.6K | SEC |
| Piscitelli Dominic | Sell | $1.4K | SEC |
| Piscitelli Dominic | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Piscitelli Dominic | Sell | $1.1M | Unusual size | SEC |
| Piscitelli Dominic | Exercise | $150K | SEC |
| Piscitelli Dominic | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Piscitelli Dominic | Exercise | $226.7K | SEC |
| Heyman Richard A. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Heyman Richard A. | Sell | $73.3K | SEC |
| Heyman Richard A. | Sell | $84.1K | SEC |
| Heyman Richard A. | Exercise | $5.6K | SEC |
| Heyman Richard A. | Sell | $3.6K | SEC |
| Piscitelli Dominic | Sell | $702.5K | SEC |
| Piscitelli Dominic | Exercise | $226.7K | SEC |
| Piscitelli Dominic | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Heyman Richard A. | Sell | $38.4K | SEC |